Date: 2017-01-17
Type of information: Treatment of the first patient
phase: 1-2
Announcement: treatment of the first patient
Company: Evgen Pharma (UK)
Product: SFX-01
Action
mechanism: SFX-01 is a synthetic and stabilised version of the naturally occurring plant compound sulforaphane, a known anti-cancer agent and neuro-protective.One proposed mechanism for the generation of resistance to hormone therapy is via the proliferation of hormone-independent breast cancer stem cells. Such cells are known to proliferate during treatment with hormonal agents and it is thought they could have the effect of repopulating the tumour to render it hormone-independent. Earlier work by Evgen Pharma with xenograft models suggests that SFX-01 has the effect of reducing the number of hormone-independent cancer stem cells.
Disease: breast cancer
Therapeutic area: Cancer - Oncology
Country: Belgium, Czech Republic, France, Spain, UK
Trial
details: The STEM (SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer) trial is investigating SFX-01 in combination with different hormone-based therapies in 60 metastatic breast cancer patients whose cancer cells are estrogen-receptor positive (ER+). The primary objectives of the STEM trial are to evaluate safety and efficacy (via tumour imaging) in patients starting to become resistant to mainstream hormone therapy. Patients will be enrolled into one of three study arms (SFX-01 in combination with either aromatase inhibitors, tamoxifen or fulvestrant) based on their current therapy. (NCT02970682)
Latest
news: * On January 17, 2017, Evgen Pharma announced that the first patient has been dosed in the company’s Phase II clinical trial of SFX-01 in breast cancer. The STEM trial is being led by Chief Investigator Dr Sacha Howell at Manchester’s Christie NHS Foundation Trust, Europe’s largest single-site cancer centre, and will include approximately 15 sites in 5 countries. The first patient was dosed on 16 January 2017 at the Cliniques universitaires Saint-Luc, the largest hospital in Brussels, Belgium.
